epz-5676 profile

ID Source	ID
PubMed CID	57345410
CHEMBL ID	3414626
CHEMBL ID	3087499
CHEMBL ID	4079133
CHEBI ID	124919
SCHEMBL ID	9106942
SCHEMBL ID	9106946
SCHEMBL ID	16129027
SCHEMBL ID	10248515
SCHEMBL ID	17433346
SCHEMBL ID	17767408
MeSH ID	M0588331

Synonym
bdbm50075098
chembl3414626 ,
CHEBI:124919
SCHEMBL9106942
SCHEMBL9106946
CS-1419
pinometostat
5'-[{cis-3-[2-(5-tert-butyl-1h-benzimidazol-2-yl)ethyl]cyclobutyl}(propan-2-yl)amino]-5'-deoxyadenosine
bdbm50443022
CHEMBL3087499 ,
S7062
epz 5676
gtpl7019
epz5676
HY-15593
1380288-87-8
epz-5676
epz-005676
8V9YR09EF3 ,
9h-purin-6-amine, 9-(5-deoxy-5-((cis-3-(2-(6-(1,1-dimethylethyl)-1h-benzimidazol-2-yl)ethyl)cyclobutyl)(1-methylethyl)amino)-.beta.-d-ribofuranosyl)-
pinometostat [inn]
pinometostat [who-dd]
pinometostat anhydrous
9h-purin-6-amine, 9-(5-deoxy-5-((cis-3-(2-(6-(1,1-dimethylethyl)-1h-benzimidazol-2-yl)ethyl)cyclobutyl)(1-methylethyl)amino)-beta-d-ribofuranosyl)-
unii-8v9yr09ef3
SCHEMBL16129027
(2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((lr,3s)-3-(2-(5-(tert-butyl)-lh-benzo[d]imidazol2yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
1380288-88-9
SCHEMBL10248515
9h-purin-6-amine, 9-(5-deoxy-5-((trans-3-(2-(6-(1,1-dimethylethyl)-1h-benzimidazol-2-yl)ethyl)cyclobutyl)(1-methylethyl)amino)-.beta.-d-ribofuranosyl)-
f66x4m38g5 ,
unii-f66x4m38g5
9h-purin-6-amine, 9-(5-deoxy-5-((trans-3-(2-(6-(1,1-dimethylethyl)-1h-benzimidazol-2-yl)ethyl)cyclobutyl)(1-methylethyl)amino)-beta-d-ribofuranosyl)-
pinometostat, trans-
(2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
AC-32709
SCHEMBL17433346
rel-n1-[(1r,2s)-2-phenylcyclopropyl]-1,4-cyclohexanediamine hydrochloride (1:2)
J-690152
DTXSID20720950
EX-A316
AKOS030238958
SCHEMBL17767408
mfcd24849416
NCGC00351597-09
NCGC00351597-14
SW220122-1
pinometostat(epz5676)
bdbm244791
us9446064, a3
DB12920
pinometostat (epz5676)
NCGC00351597-01
Q27088395
BCP14198
epz-5676;epz5676;pinometostat
BRD-K26531771-001-02-2
(2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4
(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1h-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol
CCG-270061
nsc778365
nsc-778365
(2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-(((cis-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
CHEMBL4079133
Q27277695
trans-pinometostat
Q27215234
(2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-(((3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
nsc-795144
nsc795144
NCGC00351597-02
NCGC00351597-16
NCGC00351597-10
Z3041519928

Excerpt	Reference	Relevance
" In parallel, regulatory authorities have recommended the application of physiologically based pharmacokinetic (PBPK) modeling, for example, in the recently issued FDA Strategic Plan for Accelerating the Development of Therapies for Pediatric Rare Diseases."	( Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Rioux, N; Waters, NJ, 2016)	0.43

Excerpt	Reference	Relevance
" In this study, we evaluated EPZ-5676 in combination with standard of care (SOC) agents for acute leukemias as well as other chromatin-modifying drugs in cellular assays with three human acute leukemia cell lines: MOLM-13 (MLL-AF9), MV4-11 (MLL-AF4), and SKM-1 (non-MLL-r)."	( DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. Campbell, CA; Copeland, RA; Daigle, SR; Iwanowicz, D; Johnston, D; Klaus, CR; Moyer, MP; Olhava, EJ; Pollock, RM; Raimondi, A; Scott, MP; Smith, JJ, 2014)	1.04
"To investigate the synergistic antiproliferative and inducing-apoptotic effect of EPZ-5676 combined with chemotherapeutic drugs on acute lymploblastic leukemia(ALL)."	( [Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells]. Ke, XY; Li, LH; Wang, J, 2017)	0.97
" As compared with blank control group, 5, 10 and 25 µmol/L EPZ-5676 did not affected on apoptosis of RS4;11 cells, but 5 µmol/L EPZ-5676 combined with VCR of GC possessed synergistically inducing apoptotic effect (56."	( [Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells]. Ke, XY; Li, LH; Wang, J, 2017)	0.99
"The EPZ-5676 combined with GC or VCR or VP16 possesses synergistic antiproliferative effect on RS4;11 cells, the effect of EPZ-5676 alone on apoptosis of RS4;11 cells is no significant, but the combination of low concentration EPZ-5676 with VCR or GC displays synergistically inducing apoptotic effect."	( [Effects of DOT1L Inhibitor EPZ-5676 Combined with Chemotherapeutic Drugs on Prolifiration and Apoptosis of RS 4;11 Cells]. Ke, XY; Li, LH; Wang, J, 2017)	1.31

Excerpt	Reference	Relevance
" administration; EPZ-5676 had moderate to high clearance, low oral bioavailability with a steady-state volume of distribution 2-3 fold higher than total body water."	( Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Allain, CJ; Basavapathruni, A; Boriack-Sjodin, PA; Chesworth, R; Copeland, RA; Daigle, SR; Dovletoglou, A; Jin, L; Klaus, CR; Moyer, MP; Olhava, EJ; Pearson, PG; Pollock, RM; Raimondi, A; Richon, VM; Scott, MP; Therkelsen, CA; Waters, NJ, 2014)	1
" SC administration offered improved exposure and complete bioavailability of pinometostat relative to CIV and oral administration."	( Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. Basavapathruni, A; Campbell, CT; Daigle, SR; Dovletoglou, A; Jensen, TB; Olhava, EJ; Pollock, RM; Rehlaender, BN; Stickland, KA; Truitt, BF; Waters, NJ, 2015)	0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" SC dosing in xenograft models demonstrated inhibition of MLL-r tumor growth and inhibition of pharmacodynamic markers of DOT1L activity."	( Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. Basavapathruni, A; Campbell, CT; Daigle, SR; Dovletoglou, A; Jensen, TB; Olhava, EJ; Pollock, RM; Rehlaender, BN; Stickland, KA; Truitt, BF; Waters, NJ, 2015)	0.66
" Developing drugs for pediatric malignancies also brings with it a number of unique trial design considerations, including flexible enrollment approaches, age-appropriate formulation, acceptable sampling schedules, and balancing the need for age-stratified dosing regimens, given the smaller patient populations."	( Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Rioux, N; Waters, NJ, 2016)	0.43

Class	Description
5'-deoxyribonucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	2.1696	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	25.3778	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	18.3945	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	25.3778	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	25.3778	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	25.3778	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	25.3778	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)	IC50 (µMol)	0.0119	0.0001	0.5135	7.0000	AID1199258; AID1199260; AID1437352; AID1437354; AID1437355; AID1479151
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)	Ki	0.0001	0.0000	0.0637	0.3000	AID1054112; AID1199242; AID1437357; AID1525518
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)	EC50 (µMol)	0.0090	0.0090	0.0090	0.0090	AID1054105
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
gene expression	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
heterochromatin formation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
telomere organization	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
methylation	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STAT	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
regulation of transcription regulatory region DNA binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA repair	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA damage checkpoint signaling	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleic acid binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
DNA binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3 methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3K79 trimethyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
histone H3K79 methyltransferase activity	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
cytoplasm	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
intracellular membrane-bounded organelle	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
protein-containing complex	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase, H3 lysine-79 specific	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (131)

Assay ID	Title	Year	Journal	Article
AID1199260	Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as cell growth inhibition after 14 days by Guava Viacount assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1905505	Inhibition of DOT1L in human MOLM-13 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 5 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911454	Down regulation of CDKN1B gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1525518	Inhibition of human DOT1-like Histone H3 Methyltransferase preincubated for 30 mins followed by 3H-SAM addition and measured after 120 mins	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22	Why Some Targets Benefit from beyond Rule of Five Drugs.
AID1199249	Selectivity ratio of IC50 for human WHSC1L1 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1905511	Cytotoxicity against human OCI-AML-3 cells assessed as reduction of cell viability at 1 to 40 uM incubated for 5 to 15 days by DiOC6/ propidium staining based flow cytometry analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911458	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199250	Selectivity ratio of IC50 for human PRMT1 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911487	Inhibition of HOXA9 gene expression in human MOLM-13 cells at 0.25 uM by RT-qPCR analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905530	AUC (0 to infinity) in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911491	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA3 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911467	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 6 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905506	Inhibition of DOT1L in human OCI-AML5 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 5 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911502	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA11 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911443	Down regulation of CNOT6L gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911460	Anticancer activity against human RS4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905540	Volume of distribution in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911457	Binding affinity to MBP-tagged human recombinant ENL (489 to 559 residues) incubated for 40 mins by measuring fluorescence polarization by microplate reader method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911493	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA9 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199246	Selectivity ratio of IC50 for human SMYD2 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911509	Down regulation of SSBP2 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911440	Down regulation of CDK6 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199254	Selectivity ratio of IC50 for human PRMT6 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199253	Selectivity ratio of IC50 for human PRMT5 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199257	Selectivity ratio of IC50 for human EZH2 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911450	Down regulation of RUNX1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911492	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA-A53 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911500	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA5 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1611880	Antitumor activity against human MV4-11 cells xenografted in sc dosed C57BL/6 mouse assessed as reduction in tumor growth at => MTD	2019	ACS medicinal chemistry letters, Dec-12, Volume: 10, Issue:12	New Potent DOT1L Inhibitors for
AID1199259	Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as reduction of H3K79me2 level at 1 uM after 3 to 4 days by immunoblot analysis relative to control	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911473	Induction of apoptosis in human MOLM-13 cells at 0.125 to 0.5 uM treated for 7 days by Annexin V-FITC/PI staining based flow cytometry analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199242	Inhibition of human DOT1L using oligo-nucleosome/[3H]-SAM as substrate preincubated for 30 mins followed by substrate addition measured after 120 mins by Morrison plot analysis	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1437356	Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 treated for 6 hrs measured after 8 days by Celltiter-Glo reagent based assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1911449	Down regulation of JMJD1C gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911444	Down regulation of HOXA9 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911448	Down regulation of GBE1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911506	Down regulation of HOXA10 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905542	Clearance in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1199252	Selectivity ratio of IC50 for human PRMT4 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1905512	Cytotoxicity against human MOLM-13 cells assessed as metabolic activity at 1 to 40 uM incubated for 5 to 15 days by WST-1 assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911466	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 5 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905513	Cytotoxicity against human OCI-AML-3 cells assessed as reduction of cell viability at 1 to 40 uM incubated for 5 to 15 days by WST-1 assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905537	Elimination rate constant in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911465	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 4 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911505	Down regulation of MEF2C gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905521	Tmax in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911462	Anticancer activity against human K562 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905531	AUC (0 to infinity) in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905522	Tmax in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905539	Volume of distribution in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905546	Acute toxicity in BALB/c mouse assessed as death at 10 to 20 mg/kg,iv	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911456	Binding affinity to MBP-tagged human recombinant AF9 (487 to 568 residues) incubated for 40 mins by measuring fluorescence polarization by microplate reader method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905507	Inhibition of DOT1L in human SU-DHL-4 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 5 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1437353	Binding affinity to human Avi-tagged biotinylated DOT1L (2 to 416 residues) assessed as target residence time at 100 nM by surface plasmon resonance assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1911453	Down regulation of CDK1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911445	Down regulation of HOXA5 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911503	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at MEIS1-AS3 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905547	Acute toxicity in BALB/c mouse assessed as respiratory failure at 5 mg/kg,iv measured after 6 to 7 mins	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911504	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at MEIS1 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199244	Selectivity ratio of IC50 for human GLP to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911468	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 7 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905525	Cmax in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905545	Acute toxicity in BALB/c mouse at 10 to 20 mg/kg,iv	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911459	Anticancer activity against human KOPN-8 cells harbouring MLL-ENL assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199255	Selectivity ratio of IC50 for human PRMT8 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1199248	Selectivity ratio of IC50 for human MMSET to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1437354	Inhibition of DOT1L in human HeLa cells assessed as reduction in H3K79me2 level after 72 hrs by ELISA	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1905510	Cytotoxicity against human MOLM-13 cells assessed as reduction of cell viability at 1 to 40 uM incubated for 5 to 15 days by DiOC6/ propidium staining based flow cytometry analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905527	AUC (0 to t) in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911510	Down regulation of MCM2 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199256	Selectivity ratio of IC50 for human EZH1 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1905503	Inhibition of DOT1L in human OCI-AML5 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 3 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911496	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA4 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911446	Down regulation of TUBA1B gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911497	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA6 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911512	Down regulation of GATA2 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911469	Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 9 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911498	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA10 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911514	Down regulation of MEIS1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199251	Selectivity ratio of IC50 for human PRMT3 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911488	Disruption of AF9-mediated DOT1L recruitment in human MOLM-3 cells assessed as decrease in global H3K79 methylation level at 0.125 uM measured after 8 days by Western blotting analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905533	Half life in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905528	AUC (0 to t) in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1199258	Inhibition of DOT1L in human MV4-11 cells expressing MLL-AF4 assessed as reduction of H3K79me2 level after 4 days by ELISA method	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911452	Down regulation of HOXA3 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1437355	Inhibition of DOT1L in human MOLM13 cells assessed as suppression of HoxA9 gene after 72 hrs by luciferase reporter gene assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1437357	Competitive inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate addition in presence of [3H-Me]SAM by scintillation proximity assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1911484	Inhibition of HOXA9 gene expression in human MOLM-13 cells measured at 0.125 to 0.5 uM after 6 days by RT-qPCR analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199247	Selectivity ratio of IC50 for human SMYD3 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1905534	Half life in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911461	Anticancer activity against human MV4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911508	Down regulation of SKP2 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1479151	Inhibition of recombinant human N-terminal GST-tagged DOT1L (2 to 416 residues) expressed in Escherichia coli assessed as reduction in histone H3 lysine-N-methyltransferase activity using nucleosomes after 3 hrs in presence of SAM by AlphLisa assay	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L.
AID1911511	Down regulation of HOXA11 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905502	Inhibition of DOT1L in human MOLM-13 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 3 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911481	Inhibition of MEIS1 expression in human MOLM-13 cells at 0.25 uM by RT-qPCR analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911451	Down regulation of DCUN1D1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905536	Elimination rate constant in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905514	Cytotoxicity against human SU-DHL-4 cells assessed as reduction of cell viability at 1 to 40 uM incubated for 5 to 15 days by DiOC6/ propidium staining based flow cytometry analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905548	Acute toxicity in BALB/c mouse assessed as mild tremor at 5 mg/kg,iv measured after 6 to 7 mins	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911507	Down regulation of PBX3 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911479	Inhibition of MEIS1 gene expression in human MOLM-13 cells measured at 0.125 to 0.5 uM after 6 days by RT-qPCR analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905544	Bioavailability in fasted BALB/c mouse at 5 mg/kg, iv administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911490	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA1 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905515	Cytotoxicity against human SU-DHL-4 cells assessed as reduction of cell viability at 1 to 40 uM incubated for 5 to 15 days by WST-1 assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1905504	Inhibition of DOT1L in human SU-DHL-4 cells assessed as decrease in H3K79 methylation at 1 to 10 uM using histone H3 as substrate incubated for 3 days by immunoblotting assay	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911483	Down regulation of HPGD gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911442	Down regulation of PDEA4 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1905524	Cmax in fasted BALB/c mouse at 20 mg/kg, po administered upto 600 mins by HPLC-MS/MS analysis	2022	Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
AID1911441	Down regulation of ARID1B gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911494	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA13 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911447	Down regulation of ARID2 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911495	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA2 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1199245	Selectivity ratio of IC50 for human SETD7 to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1437352	Inhibition of DOT1L (2 to 416 residues) (unknown origin) using biotinylated nucleosomes as substrate preincubated for 30 mins followed by substrate addition in presence of [3H-Me]SAM by scintillation proximity assay	2017	ACS medicinal chemistry letters, Mar-09, Volume: 8, Issue:3	Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
AID1199243	Selectivity ratio of IC50 for human G9a to IC50 for human DOT1L	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Selective inhibitors of protein methyltransferases.
AID1911501	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA7 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911513	Down regulation of AC011043.1 gene in human MOLM-13 cells by RNA-sequencing analysis	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1911499	Inhibition of methylation of H3K79 in human MOLM-13 cells assessed as inhibition of methylation at HOXA-AS2 gene cluster by chromatin immunoprecipitation assay	2022	Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11	Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-ENL.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1054112	Competitive inhibition of recombinant human DOT1L using adenosine/deazaadenosine as substrate and SAM cofactor	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
AID1054103	Antiproliferative activity against human MOLM13 cells containing MLL-AF9	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
AID1054106	Antiproliferative activity against human MV4-11 cells containing MLL-AF4	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
AID1054105	Inhibition of DOT1L (unknown origin)-mediated H3K79 methylation by cell based assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
AID1054104	Antiproliferative activity against human THP1 cells containing MLL-AF9	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
AID1346071	Human DOT1 like histone lysine methyltransferase (2.1.1.43 Histone methyltransferases (HMTs))	2013	Blood, Aug-08, Volume: 122, Issue:6	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	27 (72.97)	24.3611
2020's	10 (27.03)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (2.70%)	5.53%
Reviews	5 (13.51%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	31 (83.78%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.21	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
nadolol [no description available]	2.41	1	tetralins
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.41	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.52	2	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.21	1	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	3.21	1
atorvastatin [no description available]	2.21	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.15	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.21	1	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
inogatran inogatran: a direct low molecular weight thrombin inhibitor	2.21	1
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.21	1	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
5-iodotubercidin 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase	3.18	1	organoiodine compound
s-adenosyl-3-thiopropylamine S-adenosyl-3-thiopropylamine: decarboxylated S-adenosylhomocysteine; RN given refers to parent cpd. S-adenosyl-3-thiopropylamine : A thioadenosine that is adenosine in which the hydroxy group at C-5' is replaced by a 3-aminopropyl group.	3.18	1	organic sulfide; primary amino compound; thioadenosine
lapatinib [no description available]	2.21	1	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
wortmannin [no description available]	2.21	1	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
nsc 663284 NSC 663284: structure in first source	2.11	1	quinolone
s-adenosylhomocysteine S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.. S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.	3.63	2	adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide	cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	2.21	1	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
mometasone furoate Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.	2.21	1	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
s 1033 [no description available]	2.21	1	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
vx-745 [no description available]	2.21	1	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ellagic acid [no description available]	2.11	1	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.21	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
geldanamycin [no description available]	2.21	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	2.21	1	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
ro 42-5892 remikiren : An L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued).	2.21	1	cyclopropanes; diol; L-histidine derivative; secondary carboxamide; sulfone	antihypertensive agent; EC 3.4.23.15 (renin) inhibitor; peptidomimetic; vasodilator agent
bvt.948 [no description available]	2.11	1
ispinesib [no description available]	2.21	1	benzamides
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.21	1	lipid As
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.21	1	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
az 505 AZ 505: an SMYD2 inhibitor; structure in first source	2.11	1
navitoclax [no description available]	2.21	1	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
bix 01294 [no description available]	2.11	1	piperidines
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.15	1
epz004777 [no description available]	3.6	2	N-glycosyl compound
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	2.21	1	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
epz005687 EPZ005687: inhibits EZH2 protein; structure in first source	2.11	1	indazoles
epz-6438 tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity	3.62	2
gsk-2816126 GSK-2816126: inhibits EZH2 methyltransferase; structure in first source	2.11	1	piperazines; pyridines
(r)-pfi-2 (R)-PFI-2: a potent and selective inhibitor of SETD7 methyltransferase; structure in first source	2.11	1
enasidenib [no description available]	3.21	1	1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
lly-507 LLY-507: inhibits methyltransferase SMYD2; structure in first source. LLY-507 : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-cyano-2'-{4-[2-(3-methyl-1H-indol-1-yl)ethyl]piperazin-1-yl}[biphenyl]-3-carboxylic acid with the amino group of 3-(pyrrolidin-1-yl)propan-1-amine. It is a potent and selective inhibitor of SMYD2 and inhibits the ability of SMYD2 to methylate p53. It serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.	2.11	1

Condition	Relationship Strength	Studies
Leucocythaemia [description not available]	3.28	5
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	3.28	5
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	3	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.61	2
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Diathesis [description not available]	2.21	1
Grippe [description not available]	2.21	1
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	2.21	1
Acute Myelogenous Leukemia [description not available]	4.79	6
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	2.21	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	4.79	6
Cancer of Stomach [description not available]	2.25	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.25	1
Arthritis, Degenerative [description not available]	2.15	1
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.15	1
Cancer of Lung [description not available]	2.15	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.15	1
Acute Lymphoid Leukemia [description not available]	2.15	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.15	1
Acute Biphenotypic Leukemia [description not available]	2.11	1
Leukemia, Biphenotypic, Acute An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.	2.11	1
Breast Cancer [description not available]	2.11	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.11	1
Anemia, Hypoplastic [description not available]	3.03	1
Dysmyelopoietic Syndromes [description not available]	3.03	1
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	3.03	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	3.03	1
Benign Neoplasms [description not available]	3.46	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.46	2
Chromosomal Translocation [description not available]	3.04	1

epz-5676

Cross-References

Synonyms (74)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (54)

Molecular Functions (24)

Ceullar Components (24)

Bioassays (131)

Research

Studies (37)

Study Types

epz-5676

Cross-References

Synonyms (74)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (54)

Molecular Functions (24)

Ceullar Components (24)

Bioassays (131)

Research

Studies (37)

Study Types

Related Drugs (42)

Related Conditions (31)